Cerchietti Research Lab

Publications

Found 255 results
Filters: First Letter Of Last Name is C  [Clear All Filters]
2013
Ruan J, Luo M, Wang C, Fan L, Yang SNing, Cardenas M, Geng H, Leonard JP, Melnick A, Cerchietti L et al..  2013.  Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes.. Blood. 121(26):5192-202.
Clozel T, Yang SN, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW et al..  2013.  Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.. Cancer Discov. 3(9):1002-19.
Clozel T, Yang SN, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW et al..  2013.  Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.. Cancer Discov. 3(9):1002-19.
Clozel T, Yang SN, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW et al..  2013.  Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.. Cancer Discov. 3(9):1002-19.
Clozel T, Yang SN, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW et al..  2013.  Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.. Cancer Discov. 3(9):1002-19.
M Calvo-Vidal N, Cerchietti L.  2013.  The metabolism of lymphomas.. Curr Opin Hematol. 20(4):345-54.
M Calvo-Vidal N, Cerchietti L.  2013.  The metabolism of lymphomas.. Curr Opin Hematol. 20(4):345-54.
Cerchietti L, Melnick A.  2013.  Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment? Expert Rev Hematol. 6(4):343-5.
Cerchietti L, Leonard JP.  2013.  Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP.. Hematology Am Soc Hematol Educ Program. 2013:591-5.
Nayar U, Lu P, Goldstein RL, Vider J, Ballon G, Rodina A, Taldone T, Erdjument-Bromage H, Chomet M, Blasberg R et al..  2013.  Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies.. Blood. 122(16):2837-47.
Nayar U, Lu P, Goldstein RL, Vider J, Ballon G, Rodina A, Taldone T, Erdjument-Bromage H, Chomet M, Blasberg R et al..  2013.  Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies.. Blood. 122(16):2837-47.
Nayar U, Lu P, Goldstein RL, Vider J, Ballon G, Rodina A, Taldone T, Erdjument-Bromage H, Chomet M, Blasberg R et al..  2013.  Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies.. Blood. 122(16):2837-47.
Nayar U, Lu P, Goldstein RL, Vider J, Ballon G, Rodina A, Taldone T, Erdjument-Bromage H, Chomet M, Blasberg R et al..  2013.  Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies.. Blood. 122(16):2837-47.
2012
Barish GD, Yu RT, Karunasiri MS, Becerra D, Kim J, Tseng TW, Tai L-J, Leblanc M, Diehl C, Cerchietti L et al..  2012.  The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis.. Cell Metab. 15(4):554-62.
Fontan L, Yang C, Kabaleeswaran V, Volpon L, Osborne MJ, Beltran E, Garcia M, Cerchietti L, Shaknovich R, Yang SNing et al..  2012.  MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo.. Cancer Cell. 22(6):812-24.
2011
Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, DaGama EMGomes, Caldas-Lopes E, Beebe K, Perna F, Hatzi K et al..  2011.  Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.. Nat Chem Biol. 7(11):818-26.
Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, DaGama EMGomes, Caldas-Lopes E, Beebe K, Perna F, Hatzi K et al..  2011.  Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.. Nat Chem Biol. 7(11):818-26.
Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, DaGama EMGomes, Caldas-Lopes E, Beebe K, Perna F, Hatzi K et al..  2011.  Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.. Nat Chem Biol. 7(11):818-26.
Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, Klemm L, Kweon S-mi, Nahar R, Braig M et al..  2011.  BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition.. Nature. 473(7347):384-8.
Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim Y-mi, Herzog S, Ramezani-Rad P, Jumaa H, Müller MC et al..  2011.  BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia.. J Exp Med. 208(11):2163-74.
Shaknovich R, Cerchietti L, Tsikitas L, Kormaksson M, De S, Figueroa ME, Ballon G, Yang SNing, Weinhold N, Reimers M et al..  2011.  DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation.. Blood. 118(13):3559-69.
Shaknovich R, Cerchietti L, Tsikitas L, Kormaksson M, De S, Figueroa ME, Ballon G, Yang SNing, Weinhold N, Reimers M et al..  2011.  DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation.. Blood. 118(13):3559-69.
Cerchietti L, Damm-Welk C, Vater I, Klapper W, Harder L, Pott C, Yang SNing, Reiter A, Siebert R, Melnick A et al..  2011.  Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas.. PLoS One. 6(4):e18436.
Nahar R, Ramezani-Rad P, Mossner M, Duy C, Cerchietti L, Geng H, Dovat S, Jumaa H, B Ye H, Melnick A et al..  2011.  Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC.. Blood. 118(15):4174-8.
2010
Duy C, J Yu J, Nahar R, Swaminathan S, Kweon S-mi, Polo JM, Valls E, Klemm L, Shojaee S, Cerchietti L et al..  2010.  BCL6 is critical for the development of a diverse primary B cell repertoire.. J Exp Med. 207(6):1209-21.